透過您的圖書館登入
IP:3.235.75.229
  • 學位論文

台灣地區藥廠競爭策略形成之分析-以外商A公司為例

The Analysis of the Pharmaceutical Industry and Competitive Strategy Formulation in Taiwan - A Case Study of a Foreign Pharmaceutical Company

指導教授 : 林志鴻 賴錦璋

摘要


製藥產業為醫療產業中相當重要的一環。近年來政府雖然積極推動科技專案、主導性新產品開發輔導辦法及開發基金投資等,都將製藥工業列為重要的目標,但仍發現國內製藥工業遭遇不少瓶頸,包括國際行銷經驗及能力有待加強、業界力量分散薄弱有待整合。台灣地區國資製藥廠均屬中小型規模,且藥品重疊性高,多數廠商沒有能力研發新藥品,所生產的藥品以失去專利權再經研發的「學名藥」為主。國資廠面臨國內市場規模小、國外市場開拓不易、原料藥自給率偏低、及本身生產不具經濟規模、研發技術能力不足等問題。而加入世界貿易組織更會面臨進口關稅調降,加大其競爭壓力,而壓縮台灣藥廠生存空間。全民健保制度實施後,健保法令的變動、藥價基準、藥品再分類、醫藥分業的相繼實施,使得醫藥市場重分配,亦對製藥業者造成前所未有的衝擊。國資廠未來若無法提高產品競爭力,將會面臨市場逐漸被侵蝕的危機。 本論文將分析個案外商藥廠如何利用總部資源,因應台灣地區的情況,進行個案藥廠的內部環境、外部環境及總體環境作整體分析,制定出可行且具競爭優勢的策略進而協助個案達到使命陳述,藉由對個案外商藥廠的分析過程中,讓國資藥廠參考外商藥廠的經營模式,提昇國資藥廠的競爭實力。

並列摘要


Pharmaceutical industry has been a major role in health care system. Although the government continues to be the impetus for medical research projects, by offering counselling service and establishing investment fund for new products, domestic pharmaceutical firms still encounter great amount of obstacles.Weakness in international marketing strategy and ability, for example, and the industry strength is too diversified and need to be integrated. The drug companies in Taiwan region are middle size in scale, and their products are highly similar. Unable to afford R&D cost, most them manufacture products so-called eneric drugs, drugs that are without patent protection.Government-owned manufacture faces issues such as small domestic market, difficulty in expanding foreign market, low self-supply rate in raw materials, production does not have economies of scale, and lack of R&D ability. Taiwan accession to WTO will lower the tariff and bring more competitions, and further squeeze the room for survival for domestic firms. After the Nation Health Insurance Program established, the changes in regulations, price benchmark, redistribution, clinic/medicine separation had placed unprecedented impact on drug companies. Without improving the competitive edge, domestic firms will lose their market share eventually. This thesis will study a case where foreign pharmaceutical company utilized HQ resources, in response to the situation in Taiwan, carried out a internal, external and overall environment analysis, and formulated a feasible and competitive strategy to accomplish a mission statement.By dissecting the foreign company's analysis process, domestic firms can learn and enhance their strength.

參考文獻


3.秦慶瑤(2007),「IT IS 產業評析─ 2006年醫藥產業回顧與展望」。
2.巫文玲(2007),「IT IS 產業評析─ 2007年上半年醫藥產業回顧與展望」。
6.黃營杉譯(1999a),策略管理,台北::華泰文化事業股份有限公司。
10.榮泰生(2002),策略管理學,台北:華泰文化事業股份有限公司。
13.蘇張和惠(2003),「國際市場進入模式的選擇—印度和台灣藥廠經驗之實證研究」,國立成功大學管理學院高階管理碩士在職專班EMBA碩士論文。

被引用紀錄


劉宗玲(2016)。國際醫藥品稽查協約組織優良製造規範政策對國內西藥製劑廠策略選擇之研究〔碩士論文,淡江大學〕。華藝線上圖書館。https://doi.org/10.6846%2fTKU.2016.01035
廖益誠(2011)。全民健保政策對醫藥產業經營策略與模式的影響- 以A公司為例〔碩士論文,國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342%2fNTU.2011.10957
黃麗鈴(2008)。總額支付制度對台灣西藥產業及企業經營策略影響之研究〔碩士論文,國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342%2fNTU.2008.10362

延伸閱讀